https://o2hventures.com

o2h ventures - The o2h Human Health EIS FundFocused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel...o2h ventures - The o2h Human Health EIS Fund newsPress releasesBlogMedia CoverageEventDocumentsAboutTeamfundso2h human health KI EISo2h human health SEISo2h human health EISPortfolioknowledgehubwhat is KI EIS fund?Contact newsPress releasesBlogMedia CoverageEventDocumentsAboutTeamfundso2h human health KI EISo2h human health SEISo2h human health EISPortfolioknowledgehubwhat is KI EIS fund?ContactDon’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more The o2h human health EIS knowledge intensive fundBritain’s first HMRC approved EIS knowledge intensive fund Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel drug discovery along with enabling services, tools and AI technologiesEmail us at- invest@o2h.com Request Prospectus The o2h human health SEIS fund  The fund will invest in SEIS seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies.Email us at- invest@o2h.com Request ProspectusFund Overview Fund Fund OverviewMin Investment£25,000, there is no maximum investment.Fund Size Target Fund size of £10m.Tax AdvantagesIf you are a UK tax payer, you may benefit from for S/EIS tax reliefs on investments.DifferentiationGrassroots working relationships providing early access to deals.DiversificationWe will typically use your subscription to build a Portfolio of 5-10 unquoted and/or AIM-listed companies.LiquidityCapital is returned to you only when we are able to sell the shares in your portfolio companies.Expected Exit3-7 years. o2h will seek to exit investments after 3 years to avoid losing S/EIS reliefs. The fund may hold investments longer with a view to achieving a better exit. For similar reasons we may exit businesses earlier than 3 years notwithstanding S/EIS reliefs might be lost.Speed of InvestmentsWhile we will aim to deploy capital within 12 months, we will only invest when we find suitably exciting opportunities, which may on occasion extend this period.RisksYou should only subscribe if you are able to bear losing your entire investment. Investor Suitability Which investor type best describes you?I am a High Net-Worth IndividualI have an annual income of more than £100k or net assets of over £250k. Review & confirmI am a Sophisticated Investor I have sufficient experience with early-stage investment to certify as a sophisticated investor. Review & confirmI am neither a High Net-Worth Individual nor a Self-Certified Sophisticated Investor.I do not fit into either of the other categories. Review & confirm I am an AdvisorI represent a professional investor. Register Self certification as a high net worth individual I declare that I am a certified high net worth individual for the purposes of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. I understand that this means:I can receive financial promotions that may not have been approved by a person authorised by the Financial Conduct Authority;The content of such financial promotions may not conform to rules issued by the Financial Conduct Authority;I may lose significant rights;I may have no right to complain to either of the following:the Financial Conduct Authority; orthe Financial Ombudsman Scheme;I may have no right to seek compensation from the Financial Services Compensation Scheme. I am a certified high net worth individual because at least one of the following applies I had, during the financial year immediately preceding today’s date, an annual income to the value of £100,000 or more; I held, throughout the financial year immediately preceding today’s date, net assets to the value of £250,000 or more. Net assets for these purposes do not include: the property which is my primary residence or any loan secured on that residence;any rights of mine under a qualifying contract of insurance within the meaning of the Financial Services and Markets Act 2000 (Regulated Activities) Order 2001; orany benefits (in the form of pensions or otherwise) which are payable on the termination of my service or on my death or retirement and to which I am (or my dependants are), or may be, entitled.I accept that I can lose my property and other assets from making investment decisions based on financial promotions. financial promotions. I am aware that it is open to me to seek advice from someone who specialises in advising on investments. Sign by clicking here Sign by clicking hereSelf certification as a sophisticated investor I declare that I am a self-certified sophisticated investor for the purposes of the Financial Services and Markets Act (Financial Promotion) Order 2005. I understand that this means:I can receive financial promotions that may not have been approved by a person authorised by the Financial Conduct Authority;The content of such financial promotions may not conform to rules issued by the Financial Conduct Authority; I may lose significant rights;I may have no right to complain to either of the following:the Financial Conduct Authority; orthe Financial Ombudsman Scheme;I may have no right to seek compensation from the Financial Services Compensation Scheme. I am a self-certified sophisticated investor because at least one of the following applies: I am a member of a network or syndicate of business angels and have been so for at least the last six months prior to today's date; I have made more than one investment in an unlisted company in the two years prior to today's date I am working, or have worked in the two years prior to the today's date, in a professional capacity in the private equity sector, or in the provision of finance for small and medium enterprises; I am currently, or have been in the two years prior to today's date, a director of a company with an annual turnover of at least £1 million. I accept that I can lose my property and other assets from making investment decisions based on financial promotions. financial promotions. I am aware that it is open to me to seek advice from someone who specialises in advising on investments. Sign by clicking here Sign by clicking hereNot eligible Sorry, you are not eligible to invest in this fundRegister as an Investor You are not eligible to registerFund overviewAbout usTarget areasFund reviewsCore teamRecent investmentsRecent news featured in fund overview The o2h Human Heath EIS Fund Launch- Sunil Shah, CEO, o2h venturesTherapeutics, or coming up with next life-saving drug requires going through vast quantities of data and making various calculated guesses on how the human body will behave, this costs millions and often billions. AI has the potential to help make sense of this data in that it helps to see patterns and the AI will help make smarter predictions on how to deploy resources on research and experiments. Access to the most exciting scientific ideas through its live grassroots working relationships in the biotech community. Operating from their proprietary 2.7 acre Mill SciTech Park the fund can incubate life science companies leading to more effective decision making. The fund is structured to be S/EIS compliant providing income, inheritance and capital gains tax breaks for UK tax payers. Request ProspectusEIS fund benefitsThe Enterprise Investment Scheme is a government-backed initiative designed to encourage investment into unquoted and/or AIM-listed companies. It offers generous incentives in the form of tax reliefs, to investors who are prepared to take on the risks of this kind of investment.Income Tax ReliefLoss ReliefCapital Gains tax(CGT) ReliefCGT Reinvestment ReliefInheritance Tax(IHT) Relief Register your interest*Tax relief depends on an individual’s circumstances and may change in the future.EIS tax relief is very attractive for UK tax payersYou invest £50kEIS gives you £15k tax relief from HMRCEIS gives you £25k tax relief from HMRC IF COMPANY VALUE DOUBLESInvestment now worth £100k £50k profit+ £15k income tax relief- £10k performance incentive= £55k net profit IF VALUE STAYS THE SAMEInvestment still worth £50k £0 profit+ £15k income tax relief- £0 performance incentive= £15k net profit IF COMPANY FAILSInvestment now worth £0 £50k loss+ £15k income tax relief+ £15,750 loss relief *- £0 performance incentive= £19,250 capital loss* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees*Tax relief depends on an individual’s circumstances and may change in the future. about usThe biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotech’s for new ideas in disease areas such as cancer and neurosciences amongst others which has led to higher potential exit valuations. The fund will help widen the community of investors that will help expand early stage research in the UK.The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. our team See All Sunil ShahChief Executive OfficerSunil's Biography close Sunil ShahChief Executive Officer A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University Prashant ShahDirectorPrashant's Biography close Prashant ShahDirector A serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector. The second of these companies focused on drug discovery was acquired by a public company. Prashant co-founded o2h Ventures which is involved in seeding, incubating and investing in early stage life science and technology companies. Prashant has a BEng, MSc and an MPhil in Management. Andy MorleyChief Scientific OfficerAndy's Biography close Andy MorleyChief Scientific Officer Creative and innovative medicinal chemist with extensive knowledge and expertise. Twenty five years experience working in the pharmaceutical industry. Gary PittsCompliance Consultant, Tetractys LimitedGary's Biography close Gary PittsCompliance Consultant, Tetractys Limited Gary Pitts MA(Oxon), MA(London), MBA, FInstLM, FCMI, ACSI is a senior compliance professional of 28 year's standing, a former regulator, Head of Compliance for hedge fund Brevan Howard, Head of Compliance for Europe, Mid-East, Africa and Japan for a boutique investment bank. He is a former director of regulated firms in the UK and South Africa and has been an FCA regulated person since 2001, as well as having fulfilled regulated roles in Ireland.Gary is the founder of Tetractys Partners LLP based in London, a compliance consultancy set up in 2013 which acts for asset managers, hedge funds, brokers, fintechs and consumer credit firms, as well as delivering an extensive range of public and in-house technical training courses. He is also founder and CEO of Tetractys Ireland Limited, its Irish affiliate offering similar services to the Irish market. See All independent reviews MICAP – MI Capital Research Allenbridge – Research Center target areas Biotech add remove Novel drug research for disease areas leading to breakthrough therapeutic treatments. This could be a single asset or platform technology. AI add remove Using machine learning, predictive algorithms, big data and new technology to speed up or find new drug ideas and therapies. Enablers add remove Technologies, specialized services or platforms that enable the success of therapeutic programs. Oncology / Immunoncology add remove Oncology is the origin and development of tumours and cancer. Immunoncology works in tandem with or boosts natural immunity. Anti-ageing add remove Treatments for degeneration of cells related to physical signs of ageing as well as arthritis, alzheimers, and macular degenerative diseases (wAMD). Neuroscience add remove Research relating to the nervous system and the biological basis of memory, behaviour & consciousness. Anti-Infectives add remove Novel approaches to ensure protection against bacterial and viral attack. Genomics / DNA add remove The field of science focusing on the structure, function, evolution, mapping, and editing of genomes. Small Molecules add remove Small molecule drugs help regulate a biological target such as an enzyme, channel or receptor to modify a disease process. Biologics add remove Research covering proteins, blood, somatic cells, gene therapies, tissue recombinant therapeutics, and cell therapies. Digital Therapeutics add remove Therapeutic interventions driven by high quality software which prevent, manage or treat a spectrum of behavioural, physical and mental conditions. recent investments see all recent newso2h Ventures, Third-Time Finalist in the Best EIS Manager Specialist at the Growth Investor Awards 2024 9 August, 2024Proud Partner of the 30th Anniversary Event by EISA, celebrating three decades of Enterprise Investment Schemes (EIS) 6 August, 2024From Biotech Chemist to Family Office to Biotech Pioneer – Sunil Shah’s Exciting Journey in Biotech 31 July, 2024 fund registered with You have successfully logged out!The products shown on this website will place your capital at risk and investors may not get back the full amount invested. Past performance may not be repeated and is not indicative of future results.o2h human health funds invest in smaller and unquoted companies which carry a higher risk than many other forms of investment. There is no guarantee that target returns will be achieved. There is no liquid market for shares in unquoted companies and there can be difficulties, in valuing and disposing of investments in such companies. Tax reliefs will depend on the investors’ individual circumstance and are subject to change.o2h Ventures does not provide investment or tax advice, and the information on this website should not be construed as such. o2h Ventures recommends investors seek advice from a regulated financial adviser that specialises in EIS fund investments before making an investment decision. An investment into any of the funds managed by o2h Ventures may only be made on the basis of the information set out in the Information Memorandum and Key Information Document.The information on this website is directed at United Kingdom residents only. Please confirm you have read this warning and are happy to proceed. OK o2h Ventures LimitedHauxton House, The Mill SciTech Park, Mill Lane, Hauxton Cambridge CB22 5HX07341612481 invest@o2h.com AboutAbout UsTeamPortfolioFundsInsights and NewsKnowledge hubPress releasesBlogEventDocuments Connect with us linkedin youtube email Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums. Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance. o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors © 2024 o2h venturesPrivacy PolicyBlogContact usRisk Information Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high riskWhat are the key risks?1 – You could lose all the money you invest• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.2 – You are unlikely to be protected if something goes wrong• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)3 – You won’t get your money back quickly• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.4 – Don’t put all your eggs in one basket• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)5 – The value of your investment can be reduced• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)enusen-US1731012541https://o2hventures.com